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Supplemental Data  








The expression of selected genes in the 69 RNA samples were validated with quantitative 
PCR (qPCR).  Equal amounts of RNA were converted to cDNA using Maxima First Stand cDNA 
Synthesis Kit (ThermoFisher) following manufacturer’s recommendations.  RT-qPCR was 
performed with the CFX Connect Real-Time PCR system (Bio-Rad) using iTaq Universal Probes 
Supermix (Bio-Rad) with TaqMan Gene Expression Assay (Life Technologies) for MMP8 
(Hs01029057_m1), IFIT3 (Hs01922752_s1), FCGR1B (Hs02341825_m1), MRFAP1 
(Hs00738144_g1), HNRNPA2B1 (Hs00242600_m1) or KiCqStart Probe Assays (Sigma-Aldrich) 
for FCGR1A (HSAP_NM_000566_1), MMP9 (HSAP_NM_004994_1), APOL1 
(HSAP_NM_145343_1), PLAUR (HSAP_NM_001005377_1), MX2 (HSAP_NM_002463_1), 
GBP5 (HSAP_NM_001134486_1), GBP6 (HSAP_NM_198460_1), TNFAIP6 
(HSAP_NM_007115_1), IRF1 (HSAP_NM_002198_1).  The expression levels were determined 
by absolute quantitation method using pooled library of the 69 RNA samples as the standard curve.  
Each target gene/sample was run in duplicate, and the average was normalised to the average of 





Supplemental Table 1.  Effect of doxycycline and placebo on adverse and serious adverse events in TB patients 
  
 Overall Placebo Doxycycline Effect 
 Events/n Risk Events/n Risk Events/n Risk RR (95% CI) 
All reasons 21/30 70.0% 10/15 66.7% 11/15 73.3% 1.1 (0.69 – 1.76) 
Grade 1 and 2 events 20/30 66.7% 10/15 66.7% 10/15 66.7% 1.0 (0.60 – 1.66) 
  Nausea and vomiting  8/30 26.7% 2/15 13.3% 6/15 40.0% 3.0 (0.72 – 12.56) 
  ALT (Grade 1 and 2 events) 4/30 13.3% 2/15 13.3% 2/15 13.3% 1.0 (0.16 – 6.20) 
  Rash 4/30 13.3% 1/15 6.7% 3/15 20.0% 3.0 (0.35 – 25.69) 
Grade 1 and 2 events related to IP 8/30 26.7% 3/15 20.0% 5/15 33.3% 1.7 (0.48 – 5.76) 
Grade 3 and 4 events 1/30 3.3% 0/15 0.0% 1/15 6.7% 3.0 (0.13 – 68.26) 
Grade 3 and 4 events related to IP 0/30 0.0% - 0.0% - 0.0% - 
SAEs 2/30 6.7% 2/15 13.3% 0/15 0.0% 0.2 (0.01 – 3.85)  
SAEs related to IP 0/30 0.0% - 0.0% - 0.0% - 
 





Supplemental Table 2.  Effect of doxycycline on adverse events and serious adverse events in healthy volunteers  
 
 Doxycycline 
 Events/n Risk 
All reasons 2/10 20.0% 
Grade 1 and 2 events 2/10 20.0% 
  Nausea and vomiting  2/10 20.0% 
Grade 1 and 2 events related to IP 2/10 20.0% 
Grade 3 and 4 events 0/10 0.0% 
Grade 3 and 4 events related to IP - 0.0% 
SAEs 0/10 0.0% 
 
IP, investigational product; SAE, serious adverse events  
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Supplemental Table 3.  Pathway analysis of the co-expressed network clusters for doxycycline arm. 
 






GO:0045047 protein targeting to ER QuickGO 4.41E-53 3.29E-48 73 120 
GO:0006613 
cotranslational protein targeting to 
membrane 
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GO:0072599 
establishment of protein localization to 
endoplasmic reticulum 
QuickGO 1.26E-51 3.12E-47 73 124 
GO:0006614 
SRP-dependent cotranslational protein 
targeting to membrane 
QuickGO 8.37E-51 1.56E-46 67 105 
GO:0000184 
nuclear-transcribed mRNA catabolic 
process, nonsense-mediated decay 








6.59E-68 1.74E-63 75 409 
GSM854312 
500 
Myeloid Cells, GN.UrAc.PC, CD11b+ Ly6-
G+, Peritoneal Cavity, avg-3 
Immgen.org, 
GSE15907 
1.56E-59 2.06E-55 69 410 
GSM605846 
500 
Myeloid Cells, GN.BM, CD11b+ Ly6-G+, 
Bone marrow, avg-4 
Immgen.org, 
GSE15907 
1.75E-56 1.55E-52 67 415 
GSM854303 
500 
Myeloid Cells, GN.Arth.BM, CD11b+ Ly6-
G+, Bone marrow, avg-3 
Immgen.org, 
GSE15907 
4.02E-56 2.65E-52 67 420 
GSM854309 
500 
Myeloid Cells, GN.Thio.PC, CD11b+ Ly6-
G+, Peritoneal Cavity, avg-3 
Immgen.org, 
GSE15907 
1.77E-52 9.34E-49 64 416 
GO:0045321 leukocyte activation QuickGO 7.04E-35 2.87E-30 83 1386 
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GO:0030217 T cell differentiation QuickGO 8.15E-08 1.12E-03 13 280 
GO:0030098 lymphocyte differentiation QuickGO 8.95E-07 8.21E-03 14 404 
GO:0050852 T cell receptor signaling pathway QuickGO 2.56E-06 1.76E-02 10 214 
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Genes up-regulated in comparison of IgD+ 
peripheral blood B cells versus dark zone 
germincal center B cells. 
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Genes up-regulated in comparison of 
dendritic cells (DC) stimulated with R848 at 
2 h versus DCs stimulated with LPS (TLR4 
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Genes involved in metabolism of heme (a 
cofactor consisting of iron and porphyrin) 
and erythroblast differentiation. 
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GO:0006958 complement activation, classical pathway QuickGO 1.27E-53 2.50E-50 27 138 
GO:0002455 
humoral immune response mediated by 
circulating immunoglobulin 
QuickGO 2.24E-52 2.21E-49 27 152 
GO:0006956 complement activation QuickGO 5.16E-50 3.39E-47 27 183 
GO:0072376 protein activation cascade QuickGO 1.82E-48 8.97E-46 27 207 
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Genes involved in metabolism of heme (a 
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Human Liver Tzur09 1908genes GeneSigDB 2.62E-11 6.24E-07 17 1499 
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Genes down-regulated in erythroid 
progenitor cells from fetal livers of E13.5 
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pioglitazone [PubChem=4829] and over-
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GO:0071346 cellular response to interferon-gamma QuickGO 5.02E-18 5.05E-14 12 189 
GO:0034341 response to interferon-gamma QuickGO 1.62E-17 8.14E-14 12 208 
GO:0045087 innate immune response QuickGO 6.48E-16 2.17E-12 17 1045 
GO:0098542 defense response to other organism QuickGO 1.26E-14 3.16E-11 17 1250 





GO:0071357 cellular response to type I interferon QuickGO 1.52E-22 5.20E-19 12 95 
GO:0060337 type I interferon signaling pathway QuickGO 1.52E-22 5.20E-19 12 95 
GO:0034340 response to type I interferon QuickGO 2.56E-22 5.85E-19 12 99 
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Supplemental Figure 1.  Multiple immuno-regulatory pathways are differentially regulated 
in TB.  (A) Principal component analysis (PCA) of whole blood transcriptomes in healthy 
volunteers (n = 6, blue) and TB patients (n = 18, orange) at baseline.  Counts were normalized and 
filtered using the TMM method. The first two components of PCA are shown and their variances 
are shown in parenthesis.  (B-C) Gene set enrichment analysis of 1657 differentially regulated 
genes between TB patients and healthy volunteers (TB vs. HV) using Gene Ontology gene sets 
(B), and KEGG pathways (C).   The top 20 enriched gene sets of each category are shown.  Dotted 
line marks adjusted p-value = 0.05.  Red represents up-regulation and blue represents down-







Supplemental Figure 2.  TB modulates multiple genes in circulating cells in the KEGG 
Tuberculosis pathway relative to healthy volunteers.  Projection of differentially regulated 
genes (TB patients vs. Healthy volunteers) onto the KEGG Tuberculosis pathway (map05152) 






Supplemental Figure 3.  TB modulates multiple genes in circulating cells in the KEGG TNF 
Signalling pathway relative to healthy volunteers.  Projection of differentially regulated genes 
(TB patients vs. Healthy volunteers) onto the KEGG TNF Signalling pathway (map04668) (47-







Supplemental Figure 4.  TB dysregulates diverse pathways in whole blood relative to healthy 
volunteers.    (A) Transcript to transcript correlation analysis on all genes using CEMITool (50) 
identified 5 modules of co-expressed genes in healthy volunteers and TB patients.  Significantly 
enriched modules are shown (adjusted p-value < 0.05).  The size and intensity of the circles 
correspond to the Normalized Enrichment Score (NES, red: positive NES, blue: negative NES) of 
the modules.  (B-C) Gene set enrichment analysis of gene co-expression modules, M2 (B) and M4 
(C), which were highly expressed in TB patients.  Blood transcriptional modules (54) were used 
as gene sets.  The top 6 enriched gene sets are plotted for each module.  Dotted line marks adjusted 
p-value = 0.05.  (D-E) Baseline gene expression levels of selected genes from M2 (D) and M4 (E) 
in healthy volunteers (HV, n = 6, blue) and TB patients (TB, n = 18, orange).  TMM normalized 
counts are shown.  *Adjusted p-value < 0.05, **adjusted p-value < 0.01.  (F-G) Quantitative PCR 
(qPCR) validation of the RNA-sequencing results from M2 (F) and M4 (G) in healthy volunteers 
(HV, n = 6, blue) and TB patients (TB, n = 18, orange).  Gene expression level were normalised 
to housekeeping genes (HNRNPA2B1 and MRFAP1).  Analysis by Mann-Whitney U-test.  *p-
value < 0.05, **p-value < 0.01, ***p-value < 0.001.  Box represents 25th and 75th percentile, line 





Supplemental Figure 5.  Doxycycline results in faster normalization of immune response 
genes relative to placebo.  (A-E) Longitudinal analysis of selected immune response genes, 
SLC26A8 (A), ISF6 (B), PYGL (C), GBP6 (D), and CLEC12B (E) that were differentially 
expressed over the course of doxycycline treatment (Day 14 vs. Day 0).  TMM normalized gene 
expression at Day 0 and 14 of TB patients in placebo (green) and doxycycline (Doxy, purple) arms, 
and baseline expression of healthy volunteers (HV, blue) are plotted.  (F-K) qPCR validation of 
the RNA-sequencing results for IRF1 (F), APOL1 (G), FCGR1A (H), FCGR1B (I), GBP5 (J), and 
GBP6 (K).  Gene expression level were normalised to housekeeping genes (HNRNPA2B1 and 
MRFAP1).  Box represents 25th and 75th percentile, line is median, with whiskers denoting 






Supplemental Figure 6.  Doxycycline divergently regulates multiple pathways relative to 
placebo.  (A-B) EGSEA pathway analysis of genes significantly regulated by placebo and 
doxycycline treatment (Day 14 vs. Day 0) using Gene Ontology gene sets (A) and Hallmark 
signatures (B).  EGSEA analysis was performed individually for each arm.  The top 10 ranked 
gene sets of each arm are shown.  Gene sets are aligned in ascending value of their average rank 
in the doxycycline arm, and color intensity denotes the average rank of the gene set in each arm.  
(C) Gene set enrichment analysis of differentially regulated genes specific to doxycycline and 
placebo treatment (Day 14 vs. Day 0).  Blood transcriptional modules (54) were used as gene sets.  
The top 17 enriched gene sets in doxycycline arm are shown.  Dotted line marks adjusted p-value 





Supplemental Figure 7.  Other plasma MMPs and matrix degradation products are 
unchanged in TB patients treated with doxycycline or placebo.  Longitudinal analysis of 
plasma MMP-2 (A), MMP-3 (B), MMP-7 (C), MMP-9 (D), MMP-10 (E), EMMPRIN (F), PIIINP 
(G), and desmosine (H) concentrations at Day 0, 14 and 56 of placebo (n = 12, green) and 
doxycycline (Doxy, n = 13, purple) arms.  Protein concentrations of each subject were normalized 
to their Day 0 values.  Analysis by 2-way ANOVA with Sidak’s multiple comparisons.  Bars 







Supplemental Figure 8.  Neutrophil MMPs are unchanged in TB patients treated with 
doxycycline or placebo.  Longitudinal analysis of neutrophil MMP-8 (A) and MMP-9 (B) 
concentrations at Day 0, 14 and 56 of placebo (n = 12, green) and doxycycline (Doxy, n = 12, 
purple) arms.  Neutrophils of each subject were isolated and stimulated with live H37Rv or control 
media, and MMPs concentrations were normalized to control at each time point.  Analysis by 2-






Supplemental Figure 9.  Monocyte MMPs are unchanged in TB patients treated with 
doxycycline or placebo.  Longitudinal analysis of monocyte MMP-1 (A), MMP-3 (B), MMP-7 
(C), MMP-8 (D), MMP-9 (E), MMP-10 (F), and EMMPRIN (G) concentrations at Day 0, 14 and 
56 of placebo (n = 12, green) and doxycycline (Doxy, n = 12, purple) arms.  Monocytes of each 
subject were isolated and stimulated with live H37Rv or control media, and MMPs concentrations 
were normalized to control at each time point.  Analysis by 2-way ANOVA with Sidak’s multiple 






Supplemental Figure 10.  Analysis of other sputum MMPs and matrix degradation products 
in TB patients treated with doxycycline or placebo.  Longitudinal analysis of sputum MMP-12 
(A), MMP-13 (B), MMP-2 (C), MMP-3 (D), MMP-7 (E), MMP-10 (F), EMMPRIN (G), PIIINP 
(H), and desmosine (I) concentrations at Day 0 and 14 of placebo (n = 13, green) and doxycycline 
(Doxy, n = 13, purple) arms.  Protein concentrations of each subject were normalized to their Day 
0 values.  Analysis by 2-way ANOVA with Sidak’s multiple comparisons.  *Adjusted p-value < 
0.05, **adjusted p-value < 0.01.  Bars represent mean ± s.e.m.   
 
